Hydroxyethylamine derivatives for the treatment of Alzheimer's disease

A compound of formula (I):

• wherein
• R1 represents C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, amino, cyano, hydroxy, aryl, heteroaryl or heterocyclyl;
• R2a represents hydrogen, C1-3 alkyl, C1-3 alkoxy or halogen;
• m and n independently represent 0, 1 or 2;
• X represents CO, SO or SO2;
• p represents an integer from 1 to 3;
• R2b represents hydrogen, C1-6 alkyl, C2-6 alkenyl, halogen, C1-6 alkoxy, amino, cyano, hydroxy, aryl, heteroaryl or heterocyclyl;
• R3 represents halogen, C1-6 alkyl, C2-6 alkenyl, aryl, heteroaryl, heterocyclyl, —C1-6 alkyl-aryl, —C1-6 alkyl-heteroaryl, —C1-6 alkyl-heterocyclyl, —C2-6 alkenyl-aryl, —C2-6 alkenyl-heteroaryl, —C2-6 alkenyl-heterocyclyl, C3-8 cycloalkyl, —C1-6 alkyl-C3-8 cycloalkyl, cyano, azido, nitro, —NR7R8, —NR9COR10, —NR11SO2R12, —OR13, —SO2R14, —SR15, —C≡CR16, —C1-6 alkyl-(CF2)qCF3, —CONR17R18, COOR19, —C1-6 alkyl-NR20R21 or —C1-6 alkyl-N3, or R3 and R2b together with the phenyl group to which they are attached form a naphthyl or benzofused heterocyclic or heteroaryl ring optionally substituted by one or two C1-6 alkyl groups;
• R4 represents —C2-6 alkynyl, —C1-6 alkyl-aryl, —C1-6 alkyl-heteroaryl or —C1-6 alkyl-heterocyclyl;
• R5 represents hydrogen, —C1-10 alkyl, —C3-10 cycloalkyl, —C3-10 cycloalkenyl, aryl, heteroaryl, heterocyclyl, —C1-6 alkyl-C3-10 cycloalkyl, —C3-10 cycloalkyl-C1-10 alkyl, —C3-10 cycloalkyl-C1-6 alkyl-aryl, —C3-10 cycloalkyl-aryl, —C1-6 alkyl-aryl-heteroaryl, —C(RaRb)—CONH—C1-6 alkyl, —C(RcRd)—CONH—C3-10 cycloalkyl, —C1-6 alkyl-S—C1-6 alkyl, —C1-6 alkyl-NReRf, —C1-6 alkyl-aryl, —C1-6 alkyl-heteroaryl, —C1-6 alkyl-heterocyclyl —C1-6 alkyl-C1-6 alkoxy-aryl, —C1-6 alkyl-C1-6 alkoxy-heteroaryl or —C1-6 alkyl-C1-6 alkoxy-heterocyclyl;
• R7, R8, R9, R10, R13, R14, R15, R16, R17, R18, R19, R20 and R21 independently represent hydrogen, C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, aryl, heteroaryl, heterocyclyl, —C1-6 alkyl-C3-8 cycloalkyl, —C1-6 alkyl-aryl, —C1-6 alkyl-heteroaryl, —C1-6 alkyl-heterocyclyl or —CO—C1-6 alkyl;
• R11, R12, Ra, Rc, Re and Rf independently represent hydrogen, C1-6 alkyl or C3-8 cycloalkyl;
• Rb and Rd independently represent hydrogen, C1-6 alkyl, C3-8 cycloalkyl or —C1-6 alkyl-SO2—C1-6 alkyl;
• q represents 1 to 3;
• wherein said alkyl groups may be optionally substituted by one or more halogen, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenoxy, C3-8 cycloalkyl, amino, cyano or hydroxy groups;
• and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl groups may be optionally substituted by one or more C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, haloC1-6 alkyl, —OCF3, oxo, C1-6 alkoxy, —C1-6 alkoxy-CN, amino, cyano, nitro, —NR22COR23, —CONR22R23, —COOR22, —SO2R22, —C1-6 alkyl-NR22R23 (wherein R22 and R23 independently represent hydrogen or C1-6 alkyl), —C1-6 alkyl-C1-6 alkoxy, —C1-6 alkanol or hydroxy groups;
• or a pharmaceutically acceptable salt or solvate thereof.